BRIEF-Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 Aspire Study To Kyprolis Label
1 分钟阅读
April 30 (Reuters) - Amgen Inc:
* AMGEN RECEIVES POSITIVE CHMP OPINION TO ADD OVERALL SURVIVAL RESULTS FROM THE PHASE 3 ASPIRE STUDY TO KYPROLIS® (CARFILZOMIB) LABEL Source text for Eikon: Further company coverage: